🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

111 results for “Novo” Clear

  1. Ozempic 1 mg solution for injection in pre-filled pen, Semaglutide placebo, solution for injection in 1.5 mL pre-filled PDS290 pen injector

    Novo Nordisk A/S

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  2. Placebo (ziltivekimab), ziltivekimab

    Novo Nordisk A/S

    Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation

    phase 3 small molecule active

    1 trial

  3. Placebo (ziltivekimab), ziltivekimab

    Novo Nordisk A/S

    Acute myocardial infarction

    phase 3 small molecule active

    1 trial

  4. Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  5. Placebo, Etavopivat A 200 mg

    Novo Nordisk A/S

    Sickle cell disease

    phase 3 small molecule active

    1 trial

  6. Placebo, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10142, NNC0487-0111 B 10143, NNC0487-0111 B 10141, NNC0487-0111 B 10144

    Novo Nordisk A/S

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  7. Rybelsus 3 mg tablets, Rybelsus 14 mg tablets, Placebo (semaglutide) tablets, Rybelsus 7 mg tablets

    Novo Nordisk A/S

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  8. Rybelsus 7 mg tablets, Placebo (semaglutide) tablet, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    Novo Nordisk A/S

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  9. Rybelsus 7 mg tablets, Placebo (semaglutide) tablets, Rybelsus 3 mg tablets, Rybelsus 14 mg tablets

    Novo Nordisk A/S

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  10. Ryzodeg 100 units/mL FlexTouch solution for injection in pre-filled pen, IcoSema 700 U/mL + 2 mg/mL PDS290

    Novo Nordisk A/S

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  11. Semaglutide B 1.34 mg/mL PDS290 3.0 mL, Wegovy 2.4 mg solution for injection in pre-filled pen, Pre-filled syringe (glass) in a pre-filled pen: Semaglutide placebo Ia DV3396 pen-injector, 0.5 mL Semaglutide placebo Ib DV3396 pen-injector, 0.75 mL, Semaglutide B 0.68 mg/mL PDS290 1.5 mL, Semaglutide D 1.0 mg/mL DV3396, Semaglutide D 2.0 mg/mL DV3396, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Semaglutide B 3.2 mg/mL PDS290 3.0 mL

    Novo Nordisk A/S

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  12. Sogroya 15 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 5 mg/1.5 mL solution for injection in pre-filled pen, Sogroya 10 mg/1.5 mL solution for injection in pre-filled pen, Norditropin FlexPro, injektionsvæske, opløsning i fyldt pen

    Novo Nordisk A/S

    Growth Hormone Deficiency in children

    phase 3 small molecule active

    1 trial

  13. Sterile 0.9% (w/v) sodium chloride solution in single-use PFS, Novolizer Salbutamol 100 microgrammes/dose, poudre pour inhalation

    GlaxoSmithKline Biologicals S.A.

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  14. TEMOZOLOMIDE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, saline solution for infusion

    Novo mesto

    Newly diagnosed Glioblastoma

    phase 3 small molecule active

    1 trial

  15. Tecentriq 840 mg concentrate for solution for infusion

    Novo mesto

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 3 small molecule active

    1 trial

  16. UVEDOSE 100 000 UI, solution buvable en ampoule

    Novo mesto

    Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia

    phase 3 small molecule active

    1 trial

  17. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143

    Novo Nordisk A/S

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  18. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  19. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide

    Novo Nordisk A/S

    Cardiovascular disease

    phase 3 small molecule active

    1 trial

  20. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, METFORMIN , INSULIN DEGLUDEC , INSULIN (HUMAN) , INSULIN GLARGINE , cagrilintide semaglutide, INSULIN DETEMIR , Placebo + Placebo

    Novo Nordisk A/S

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  21. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide

    Novo Nordisk A/S

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

  22. cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, Placebo + Placebo

    Novo Nordisk A/S

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  23. cagrilintide, Placebo, cagrilintide, cagrilintide, cagrilintide

    Novo Nordisk A/S

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  24. cagrilintide, cagrilintide, cagrilintide, cagrilintide, Placebo

    Novo Nordisk A/S

    Overweight and obesity

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources